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Abstract: Cancer antigen CA125 represents an extracellular part of transmembrane mucin MUC16 and may be expressed in tissues
of the male reproductive tract. It reaches human seminal plasma (hSP) after undergoing the main processes involved in protein
speciation: synthesis, posttranslational modifications, compartmentalization, and auto/proteolytic degradation. This study was aimed
at profiling CA125-immunoreactive species in hSP from healthy subjects as a specific and unexplored source of this tumor-associated
antigen expressed under normal physiological conditions. High molecular mass components from total hSP and corresponding
acid-soluble hSP preparations were analyzed. The results indicated that antibodies recognizing two distinct immunogenic areas of
CA125 antigen exhibited a common pattern of immunoreactive bands affected by low pH and reducing agents. They comprise a large,
heavily glycosylated moiety and a mixture of low glycosylated species ranging from 100 to 150 kDa. High molecular mass CA125immunoreactive smears overlapped core 2 O-glycans and the Lex glycotope, the latter also being abundant on distinct lower molecular
mass immunoreactive bands. Within the bulk of normal hSP mucins, the CA125 antigen is present in low amounts and resides on
heterogeneously glycosylated species that may be proteolysis-derived and sensitive to redox environments. Both factors influence the
composition of hSP and therefore might affect speciation of mucin16 under normal and pathological conditions.
Key words: CA125 antigen, human seminal plasma, proteolysis, conformational epitope, Lewisx

1. Introduction
CA125 antigen is a human cancer antigen identified
through binding by OC125, which is a monoclonal IgG1
antibody produced by somatic hybridization of spleen
cells from BALB/c mice immunized with the OVCA
433 epithelial ovarian cancer cell line established from a
patient with serous papillary cystadenocarcinoma (Bast
et al., 1981). Since this initial finding in 1981 indicating
a specific association of CA125 to ovarian neoplasms, a
wealth of literature on its clinical application for screening,
detection, and management of gynecologic malignancies
has accumulated (Montz, 1992, Bergan et al., 2007).
Currently, it is recognized as a serum tumor marker for
routine monitoring of patients with ovarian cancer (Duffy
et al., 2005).
Quantification of CA125 antigen in circulation is
actually related to measuring the concentration of a
proteolytically released extracellular portion of mucin
16 (MUC16). Thus, investigations of its basic molecular
nature, i.e. the high molecular mass glycoprotein complex
where it resides, and partial cloning of the muc16 gene
* Correspondence: ninoslavm@inep.co.rs

led to its definition as a repeating peptide epitope on
MUC16 (Yin et al., 2001). The epitope map of CA125 is,
however, very complex and varies among mucin molecules
expressed under different pathophysiological conditions
and from different sources. This results in typical/unique
patterns sharing some commonality (Nustad et al., 2002).
Structural data obtained on CA125/MUC16 indicated
extreme heterogeneity, probably due to the existence of
molecular species differing in mass and glycosylation.
CA125-immunoreactivity was associated with high
molecular mass macromolecular moieties of 3–5 MDa
mucin and 400 kDa–200 kDa precursors, but also with low
molecular mass species at 55 and 40, down to 10–15 kDa
(Hanisch et al., 1985; Nustad et al., 1998; Yin et al., 2001).
As for glycosylation, the total glycan content varied from
moderate, as in glycoproteins, to extremely high (more
than 28%), as in mucins (Kui Wong et al., 2003). Relatively
high abundance of N-glycans, not typical for other mucins
and diverse O-glycan associated epitopes such as CA19-9
and sTn, have been reported (Davis et al., 1986; Kui Wong
et al., 2003; Akita et al., 2012).
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The available data on CA125 in human seminal plasma
(hSP), where its concentration is relatively low, are very
scarce (Halila, 1985; Matorras et al., 1994; Meisser et al.,
1996). The results of proteomic analyses differ, since one
study reported CA125/MUC16 as a constituent of hSP,
whereas another failed to detect this antigen (Russo et al.,
2006; Milardi et al., 2012). In general, conflicting data on
the presence of other types of mucins were also observed
when hSP was analyzed. This may be partially related
to known interindividual sample variations due to the
predominance of content of extracellular origin (Russo et
al., 2006; Yamakawa et al., 2007).
Characterization of CA125 antigen from hSP fits
within the concept of protein speciation aiming at the
description and characterization of all molecular species
of a single protein/molecule in a specified subproteome
and time. Thus, the CA125 antigen reaches hSP after
undergoing four main processes involved in protein
speciation: synthesis, posttranslational modification,
compartmentalization (membrane or secreted form), and
auto/proteolytic degradation during liquefaction (Jungblut
et al., 2008; Schluter et al., 2009). Taking this into account,
we hypothesize that CA125 in human seminal plasma
exists as a heterogeneous molecular species.
The present study represents an initial contribution
to defining the glyco-immunoreactive profile of CA125
in hSP as a source of antigen expressed under normal
physiological conditions. In these terms, we add new value
relevant for general basic knowledge on this still-elusive
biomarker mucin molecule. Previous investigations of
cancer- and noncancer-derived CA125 antigen from other
sources revealed distinct properties that influence its
potential as a biomarker and modify its ligand capacity and
subsequent biological activity (Jankovic et al., 2008; Mitic
et al., 2012), involving the glycan part of the molecule.
These data were acquired using plant lectins: proteins
that bind to specific configurations of oligosaccharide
molecules, based on their composition, linkage, and type.
They are also used here as a tool for analysis of seminal
plasma CA125-associated glycans.
As a specific and unexplored source, hSP may be of
interest in the context of MUC16/CA125 speciation, since
signatures of its molecular species, in terms of molecular
mass epitope distribution and glycosylation, may reflect
different physiological processes in the male reproductive
tract.
2. Materials and methods
Biotinylated plant lectins: Wheat germ agglutinin (WGA),
Sambucus nigra agglutinin (SNA), Phaseolus vulgaris
erythroagglutinin (PHA-E), biotinylated goat antimouse
IgM antibody (affinity purified, specific for Mµ chain, Cat.
No. BA-2020), biotinylated goat antimouse IgG (Cat. No.
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BA-9200), and Elite Vectastain ABC kit were from Vector
Laboratories (Burlingame, CA, USA). Mouse monoclonal
antihuman Lewisx (anti-Lex, Cat. No. 434631), and Lewisy
(anti-Ley, Cat. No. 434636) antibodies, class IgM, and
Immobilon-P PVDF membrane were obtained from Merck
KgaA (Darmstadt, Germany). Monoclonal anti-CA125
antibody (clone X306 and clone X325, Cat. No. 4C29) was
from HyTest (Turku, Finland). Bovine serum albumin (BSA)
was from Sigma-Aldrich/Sigma (St. Louis, MO, USA).
The silver stain kit and SDS-PAGE molecular mass
standards (broad range) were from Bio-Rad (Hercules,
CA, USA). Pierce ECL Western Blotting Substrate
was purchased from Thermo Scientific (Rockford, IL,
USA). Sepharose 4B was from Pharmacia AB (Uppsala,
Sweden). CA125 concentration was quantitated
using the commercially available ELSA CA125 II
immunoradiometric assay (Cisbio Bioassays, Codolet,
France), according to the manufacturer’s instructions.
All other reagents were p.a.
2.1. Human semen samples
Leftover specimens of human semen from anonymized
subjects taken for routine analysis of fertility were obtained
according to guidelines of ‘The rules of procedures
of Ethics committee of INEP’ (No. 02-832/1). Sperm
parameters were assessed according to the recommended
criteria of the World Health Organization (1999) in terms
of numbers, morphology and motility. Samples with
over 20 × 106 spermatozoa/mL, with >70% presenting
normal morphology and >50% motility, were deemed
normospermic and used for further analysis. Sperm cells
and other debris were removed from the ejaculate by
centrifugation at 800 × g for 20 min. Seminal plasma was
stored at –20 °C until required.
2.2. Isolation of acid-soluble mucin-enriched fraction by
perchloric acid (PCA) precipitation
An acid-soluble mucin-enriched fraction was isolated
from pooled individual hSP samples (n = 15) by
PCA precipitation as previously described with slight
modifications (Baeckström et al., 1991). The supernatant,
containing proteins soluble in 0.1 M PCA, was separated
by centrifugation at 7000 × g for 30 min, additionally
filtered and then neutralized by the addition of 1M TRIS,
pH 8.0. It was dialyzed against 0.05 M phosphate buffered
saline (PBS), pH 7.2, for 18 h at 4 °C and stored at –20
°C until further use. Concentration of CA125 antigen
in seminal plasma samples was determined using ELSA
CA125 II immunoradiometric assay, and samples with
detectable levels of CA125 antigen (15–325 IU/mL) were
used for further analysis.
2.3. Iodination
Anti-CA125 antibody (clone X306) was labeled with
radioiodine (125I) using the chloramine T method as
described by Greenwood et al. (1963). The labeled
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antibody was separated from free iodine on a Sephadex
G-75 column (10 mL bed volume) and equilibrated with
0.05 M PBS, pH 7.2, containing 0.05% bovine serum
albumin.
2.4. Gel filtration
The sample (1 mL of total hSP or acid-soluble hSP
preparation) was loaded on a Sepharose 4B column (bed
volume 35 mL, 1.2 × 31.3 cm), equilibrated, and eluted
with 0.05 M PBS, pH 7.2, at 60 mL/h. The elution was
monitored by measuring absorbance at 280 nm in each
fraction (1 mL). The peak fractions starting to elute at void
volume (fractions 17–21) were pooled for further analysis.
Alternatively, the gel filtration pull-down assay was
performed as follows: the acid-soluble hSP preparation
was incubated with an I125-anti-CA125 antibody overnight
at room temperature (RT) and subjected to gel filtration.
Elution was monitored by measuring radioactivity (cpm)
in each fraction on a Wallac Wizard 1470 Gamma Counter
(Perkin Elmer, Monza, Italy).
2.5. SDS-PAGE and Western and dot blot
Samples were subjected to electrophoresis under reducing
(in a sample buffer containing 5% β-mercaptoethanol) or
nonreducing conditions (in a sample buffer without 5%
β-mercaptoethanol) on 6%/10% separating gels and 4%
stacking gel, according to Laemmli (1970). The gel was
calibrated with SDS-PAGE molecular weight standards
(broad range) (Bio-Rad) and stained using silver nitrate.
Alternatively, proteins were transferred onto
Immobilon P PVDF membrane (Merck KgaA) by semidry
blotting using a Trans-blot SD (Bio-Rad). The conditions
were as follows: transfer buffer and 25 mM TRIS containing
192 mM glycine and 20% methanol, pH 8.3, under a
constant current of 1.2 mA/cm2 for 1 h. The membrane
was blocked with 3% BSA in 0.05 M PBS, pH 7.2, for 2 h at
RT, and then subjected to immuno- or lectin blot analysis.
For dot blot, the samples (3 µL droplets) were instilled
on the membrane, dried, and blocked as described above.
2.6. Immunoblot
For immunoblotting, the membrane was incubated with
the appropriate antibodies (anti-CA125: 2 µg/mL; anti-Lex
and anti-Ley: 1:500) overnight at 4 °C. After a washing step,

the appropriate biotinylated secondary antibody (1:10,000
goat antimouse IgG or 1:2000 IgM) was added and left for
1 h at RT. The membrane was then rinsed and the avidin/
biotinylated horseradish peroxidase (HRPO) mixture
from the Elite Vectastain ABC kit (prepared according to
the manufacturer’s instructions) was added, followed by
incubation for 30 min at RT. After another washing step,
the blots were visualized using Pierce ECL Western blotting
substrate according to the manufacturer’s instructions.
For determining nonspecific binding, the primary
antibody was omitted from this procedure.
2.7. Lectin blot
The membrane was incubated with the chosen biotinylated
plant lectin (Table) at 0.2 µg/mL in 0.05 M PBS, pH 7.2,
for 1 h at RT and then washed six times in 0.05 M PBS,
pH 7.2. HRPO from Vectastain Elite ABC kit was added
and incubated for 30 min at RT. The membrane was then
rinsed again six times in 0.05 M PBS, pH 7.2, and proteins
were visualized using ECL substrate solution, according to
the manufacturer’s instructions.
3. Results
3.1. Patterns of CA125-immunoreactive species in hSP
preparations as revealed by monoclonal anti-CA125
antibodies
The mucin-enriched preparation from hSP isolated on
the basis of acid solubility was subjected to gel filtration
on a Sepharose 4B column to separate high molecular
mass from low molecular mass components. Protein peak
fractions starting to elute at void volume (Figure 1A)
exhibited CA125-immunoreactivity, as shown by dot blot
(Figure 1B) and anti-CA125 antibody pull-down assay
(Figure 1C).
Under denaturizing, in both reducing and nonreducing
conditions the acid-soluble sample showed faint silver
staining (Figures 2A and 2B) in the stacking gel and at the
border of the stacking and separating gels, characteristic of
mucin appearance on SDS-PAGE. In addition, the staining
revealed several bands in the range of 45–130 kDa, with
characteristic enrichment of particular bands under
reducing conditions (Figure 2A).

Table. Carbohydrate-binding specificities of used plant lectins.
Lectin

Preferred oligosaccharide structure*

Wheat germ agglutinin (WGA)

GlcNAcβ1,4GlcNAcβ1,4GlcNAc > GlcNAcβ1,4GlcNAc > GlcNAc

Phaseolus vulgaris erythroagglutinin (PHA-E)

Man3(GlcNAc β1,4)GlcNAc2-Asn

Sambucus nigra agglutinin (SNA)

Neu5Acα2,6Gal/GalNAc

*GlcNAc: N-acetylglucosamine; Man: Mannose; GalNAc: N-acetylgalactosamine; Gal: Galactose; Neu5Ac: N-acetylneuraminic acid,
sialic acid.
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Figure 1. Separation of the CA125-immunoreactive fraction from a human seminal plasma acid-soluble preparation. A mucin-enriched
preparation from hSP isolated on the basis of acid solubility was subjected to gel filtration on Sepharose 4B and elution was monitored
by measuring absorbance at 280 nm (A). The presence of CA125 antigen in each fraction (1 mL) was detected by dot blot using antiCA125 antibody (clone X325) as described in Section 2 (B). The high molecular mass CA125-immunoreactive peak (pooled fractions
17–23) was used for further analysis. The peak (A, fractions 35–60) comprising low molecular mass acid-soluble proteins was not
considered. CA125-immunoreactivity was additionally tested by incubating the acid-soluble hSP preparation with an iodinated antiCA125 antibody (clone X306), followed by gel filtration on Sepharose 4B. Elution was monitored by measuring radioactivity (cpm,
counts per min) in each fraction (C). Peak (fractions 17–23) represents bound I125anti-CA125 antibody and peak (fractions 39–59)
represents unbound I125anti-CA125 antibody.

Figure 2. Protein patterns of the high molecular mass CA125-containing fraction separated from human seminal plasma acid-soluble
preparations. Samples were subjected to SDS-PAGE on 6% polyacrylamide gel under reducing (A) or nonreducing (B) conditions,
followed by silver staining. The numbers on the right indicate the position of molecular mass standards (kDa).
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Under
nonreducing
conditions,
CA125immunoreactivity was seen as faint smears associated with
high molecular mass glycoproteins and also as smeared
bands between 116 and 200 kDa, using both X306
(Figure 3A) and X325 (Figure 3B) antibodies. However,
no immunoreactive bands were detected under reducing
conditions, irrespective of the antibody used (Figures 3C
and 3D).
To resolve the possible influence of exposure to low pH
conditions during PCA precipitation, high molecular mass
components separated from total hSP by gel filtration were
analyzed by immunoblot using the same procedure as for
the acid-soluble preparation. CA125-immunoreactivity
(using the X325 antibody) was found to be preserved under
reducing conditions, associating with bands between 116
and 200 kDa and an additional smeared band at 100 kDa
(Figure 3E). Using the X306 clone gave the same pattern
with very faint staining (data not shown).
3.2. Patterns of glycan-containing molecular species in
hSP preparations as revealed by lectins and carbohydratebinding antibodies
To complement data on size distribution and conformation
in protein-dependent CA125-immunoreactive species,
the patterns of glycans across high molecular mass
fractions from total hSP and corresponding acid-soluble
preparations were analyzed (Figure 4).
In total hSP, intense staining of the smear in the stacking
gel was observed under reducing conditions, using WGA
(specific for core 2 O-glycans containing polylactosamine

chains) (Figure 4A) and antibodies to fucosylated Lewis
glycotopes, Lex and Ley (Figures 4B and 4C). In addition,
intense Lex-reactive bands were also detected at 100 and
130 kDa (Figure 4B). In contrast to this, SNA (specific
for alpha 2,6Gal/GalNAc in N-glycans and sTn antigen in
O-glycans) and PHA-E (specific for bisected N-glycans)
stained bands faintly in the lower molecular mass region
of 66–150 kDa (Figures 4D and 4E).
Thus, anti-Lex–stained bands (high and lower
molecular masses) and partially SNA-, PHA-E- and antiLey–stained bands (lower molecular masses) resemble/
overlap with the CA125-immunoreactive bands in total
hSP (Figure 3E).
In the acid-soluble preparation, under reducing
conditions, WGA-, Lex-, and Ley-reactive smears were also
observed (Figures 4F–4H), but differences were found in
the lower molecular mass region. Anti-Lex– and anti-Ley–
staining was reduced, if present at all, and associated with
lower molecular mass bands than those observed for total
hSP. As for SNA- and PHA-E–reactive species, they were
numerous and intense, exhibiting partially overlapping
patterns of closely migrating bands (Figures 4I and 4J).
4. Discussion
Using monoclonal antibodies recognizing two previously
defined main immunogenic areas of the CA125 antigen
(Nustad et al., 1996), overlapping patterns of distinct
immunoreactive species were observed in normal hSP.
It comprised a large, heavily glycosylated moiety, as well

Figure 3. Patterns of CA125-immunoreactive species in human seminal plasma. CA125-immunoreactive fractions from the mucinenriched acid-soluble preparation were separated via gel filtration and subjected to SDS-PAGE electrophoresis on 10% gel under
denaturizing nonreducing (A, B) or reducing (C, D) conditions, followed by immunoblot analysis using anti-CA125 antibodies: clone
X306 (A, C) or X325 (B, D). Immunoblot analysis of the high molecular mass fraction separated from total hSP by gel filtration using the
same procedure as for the acid-soluble preparation using antibody X325 indicated preserved CA125-immunoreactivity under reducing
conditions (E). The band at 45 kDa results from nonspecific binding. The numbers on the right indicate the position of molecular mass
standards (kDa).
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Figure 4. Carbohydrate distribution across the high molecular mass CA125-containing fraction from human seminal plasma. CA125immunoreactive fractions from total hSP (A–E) and acid-soluble preparation (F–J) were separated via gel filtration and subjected to
SDS-PAGE electrophoresis on 10% gel under reducing conditions, followed by detection using biotinylated plant lectins: WGA (A, F),
anti-Lex (B, G), anti-Ley (C, H), SNA (D, I), or PHA-E (E, J). The numbers (left) indicate the position of molecular mass standards (kDa).
Curly brackets refer to CA 125-immunoreactive regions presented in Figure 3.

as a mixture of low glycosylated proteins ranging from
97 kDa to well over 200 kDa, all supposed to originate
from monomeric MUC16, which is estimated to be the
largest member of the mucin family, having an amino
acid moiety of 22156 AA (O’Brien et al., 2001, 2002; Perez
and Gipson, 2008). MUC16 can be cleaved between the
N- and C-terminal fragments, possibly in the SEA (sea
urchin sperm protein, enterokinase, and agrin) domain,
with potential influence on immunoreactivity, since both
epitopes for OC125 and M11-like antibodies contain parts
of two consecutive SEA domains with a linker (Maeda et
al., 2004; Blalock et al., 2008). So far, proteomic profiling
identified a 2351.2 kDa protein/spot as high molecular
mass MUC16/CA125 (Milardi et al., 2012), but a CA125immunoreactive band at 130 kDa was also observed in
another immunoblot study (Halila, 1985). Although
the occurrence of several low molecular mass CA125immunoreactive species was reported for different sources,
their origin is still not elucidated, in contrast to the high
molecular mass species. They are supposed to result from
auto/proteolytic activity and muc16 gene polymorphism,
but there is also a suggestion that some of them are actually
cross-reactive molecules (Weiland et al., 2012; McLemore
et al., 2016).
The results obtained in this study indicate common
patterns of immunoreactive species as revealed by both the
X306 and the X325 antibody. The latter antibody has the
strongest similarity to antibody M11, which is generally
reactive with all the repeats and more represented,
whereas X306 is an OC125-like antibody reported to have
a restricted epitope distribution that nonetheless exhibits
some level of cross-reactivity (Weiland et al., 2012). Thus,
in the context of origin and specificity/identity of the
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lower molecular mass components, the patterns obtained
might be related to distinct (auto) proteolytically released
glycospecies containing CA125 epitope(s) recognized by
these two antibodies from different antibody groups.
The CA125 epitope(s) is defined as a conformational
epitope, although there is no consensus about its structure.
This epitope is reported to be localized in the 21 amino acid
loop of the tandem repeat region and includes disulfide
bonding of cysteine between positions 59 and 79 (O’Brien
et al., 2001, Maeda et al., 2004). On the other hand, there
are data indicating that it is not a continuous epitope,
but is dependent on the secondary structure of MUC16
tandem repeats (Bressan et al., 2013). In relation to all this,
recognition of CA125 is supposed to be dependent on the
conditions used for immunodetection as well as on the
molecular forms/species present in the sample evaluated.
Data obtained using various anti-CA125 antibodies
indicated immunoreactive bands in samples of different
origin under both reducing and nonreducing conditions.
This may be due to the renaturated conformation of the
SEA domain upon Western blot (Bressan et al., 2013), but
it was also suggested that epitope conformation on shorter
moieties may be lost, leading to a lack of immunoreactive
bands of lower molecular mass.
In this study, the detection of CA125-immunoreactive
bands was found to be dependent on the antigen source,
i.e. whether examining total unfractionated hSP or
corresponding acid-soluble hSP preparations. Thus,
under reducing conditions, CA125 immunoreactivity
was preserved in total hSP, but lost in acid-soluble
hSP preparations, which may suggest sensitivity of the
epitopes to low pH. A mucin preparation obtained at a
low pH would probably be prone to partial (hydrophobic)
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aggregation (Hong et al., 2005) but it has been reported
that similar conditions could promote protease activity
or lead to autoproteolytic cleavage in the sample (Lidell
et al., 2003). A possible explanation is that low pH
induces proteolytic cleavage, resulting in nicked mucin
molecules held together under nonreducing conditions,
but destroyed under reducing conditions, as seen for
MUC5AC and MUC5B in cystic fibrosis (Thornton et
al., 1991; Davies et al., 2007; Henderson et al., 2014). This
influence on conformation and presentation of the CA125
epitope may lead to the observed changes in the patterns
of immunoreactive bands under nonreducing versus
reducing conditions. Moreover, proteolytic cleavage of
any component in the sample can result in the release of
additional low molecular mass fragments migrating to the
same position as immunoreactive bands, impairing their
accessibility to antibody binding.
It was shown that neither N- or O-glycosylation
substantially influence the binding of OC125- and M11antibodies (Marcos-Silva et al., 2014) but this should
not be neglected, since mucins are highly glycosylated
molecules. In general, mucins, including MUC16, are
characteristic for so-called protease-sensitive naked
region(s) containing no or little carbohydrates and
highly O-glycosylated region(s) rich in Ser, Thr, and Pro
that are resistant to proteolysis (Roberton et al., 1989;
Thornton et al., 1990). Having in mind all the limitations
of indirectly approaching glycosylation of CA125immunoreactive species, we compared the combined
glyco/antigenic/molecular mass profiles of total hSP
with the corresponding acid-soluble preparations under
reducing conditions. As it is more specific and demanding,
carbohydrate binding was used to obtain a comprehensive
profile of lower molecular mass protein species. Taken
together, lectin-/anti-Lewis antigen-binding patterns
indicated that the Lex glycotope overlapped with CA125immunoreactive bands across the entire range of observed
molecular masses. Loss of immunoreactivity in the acidsoluble preparation under reducing conditions may be
related to the presumed proteolytic degradation, since less
intense staining of smears and a shift to lower molecular
mass bands was observed in the Lex-pattern. In accordance
with this, patterns of lower molecular mass SNA- and
PHA-E-reactive bands indicated greater abundance over
a broader mass range in acid-soluble preparations. These
lectin-binding patterns suggest that, under reducing
conditions, other glycosylated proteins with molecular
mass corresponding to low abundant SNA/PHA-Ereactive CA125-derived species may be released and may
obscure them from view. To illustrate this, the observed
130 kDa band, enriched under reducing conditions, does
not contribute to CA125-immunoreactivity associated
with the band having the same electrophoretic mobility.

This band was previously suggested to be associated with
MUC5B as the main hSP mucin (Roberton et al., 1989;
Nordman et al., 2002).
Extremely complex mucin structures influence
accessibility and proper exposure of particular epitopes
(Bjerner et al., 2002). This is especially apparent when
using antibodies specific for the protein core, i.e. a distinct
amino acid sequence in particular tandem repeat(s).
Thus, an immunometric test usually measures only one
fraction of a heterogeneous analyte in the examined
sample (Bjerner et al., 2002; Nustad et al., 2002), as many
epitopes residing on different molecular mass forms are
inaccessible or the antibodies used have low affinity for
them (Nustad et al., 2002). The same might hold true for
immunoblot analysis, which is additionally influenced by
the mode of sample preparation and binding reactions to
the immobilized mucin molecule.
Within the bulk of abundant hSP mucins, immunoblot
analysis indicated recurrent CA125- immunoreactive
bands of lower molecular mass in the region present in
most hSP preparations as referent and discriminative.
However, caution must be applied, since they seem
to be proteolysis-derived and sensitive to the redox
environment. Both conditions are known to influence
the nature/composition of hSP significantly (LaFlame et
al., 2013; Sharma et al., 2013) and could independently
affect speciation of particular molecules under both
normal and pathophysiological conditions. As the pattern
of CA125 molecular species may change in different
pathophysiological conditions, it could be potentially
utilized as a diagnostic target where alterations in
glycosylation denote an ongoing pathological change.
Thus, these alterations in mucin(s) glycosylation coupled
with activity of hSP proteolytic enzymes and varying pH
conditions in the female reproductive tract (Suarez and
Pacey, 2006) could make it more sensitive or resistant
to environmental conditions and consequently affect its
biological functions.
In general, there are conflicting views about the structure
of CA125 molecules from different sources. These may be
due to both specificities of the structure and limitations of
available experimental techniques (Bouanane and Miled,
2010). Together with earlier findings, the results obtained
here suggest that a combination of different affinity- and
immunoreactivity-based approaches, including special
care regarding sample collection and preparation, is
necessary for CA125/MUC16 to be used as a reliable
biomarker in the hSP proteome.
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